Mylan NV and Momenta Pharmaceuticals Inc. said Friday they would jointly develop and commercialize six biosimilars.
Mylan will make an upfront cash payment of $45 million to Momenta and could pay up to $200 million if milestones are reached. Each company will equally share the development costs and eventual profits.
How do you turn that into today's announcement?
What I saw today was Craig saying that Momenta has plenty of money and they're going to blow through it in no time. We'll be back at the well within 2 years.....